What Is the Treatment of Acquired Long QT Syndrome?

Acquired long QT syndrome is a disorder of cardiac repolarisation characterised by pathological prolongation of the QT interval, carrying risk of life-threatening ventricular arrhythmia. Structured, evidence-based management is essential to reduce that risk.

Treatment Approach

Current evidence supports a combined strategy for patients with acquired LQTS. Pharmacological therapy is a central component, and in patients who remain at risk, device-based intervention is incorporated as a further layer of protection. The full protocol specifies precisely when and how each element is applied.

The regimen involves both a pharmacological agent and, where indicated, an implantable cardiac device — with clear criteria determining which patients require the device in addition to medication.

Complete decision criteria, sequencing, and management details are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehac262

ICD implantation is recommended in patients with LQTS who are symptomatic while receiving beta-blockers and genotype-specific therapies.

View source ↗